NCT00264160View on ClinicalTrials.gov

Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

August 31, 2009

Conditions
Leukemia, Myeloid, Chronic
Interventions
DRUG

AMN107

Trial Locations (4)

Unknown

Novartis Investigative Site, Haifa

Novartis Investigative Site, Jerusalem

Novartis Investigative Site, Petah Tikva

Novartis Investigative Site, Tel Litwinsky

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY